Details for New Drug Application (NDA): 022074

✉ Email this page to a colleague

NDA 022074 describes SOMATULINE DEPOT, which is a drug marketed by Ipsen Pharma and is included in one NDA. It is available from one supplier. Additional details are available on the SOMATULINE DEPOT profile page.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.

Summary for 022074

Tradename:	SOMATULINE DEPOT
Applicant:	Ipsen Pharma
Ingredient:	lanreotide acetate
Patents:	0

Pharmacology for NDA: 022074

Mechanism of Action	Somatostatin Receptor Agonists

Suppliers and Packaging for NDA: 022074

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074	NDA	Ipsen Biopharmaceuticals, Inc.	15054-1060	15054-1060-4	1 POUCH in 1 CARTON (15054-1060-4) / 1 SYRINGE in 1 POUCH / .2 mL in 1 SYRINGE
SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074	NDA	Ipsen Biopharmaceuticals, Inc.	15054-1090	15054-1090-4	1 POUCH in 1 CARTON (15054-1090-4) / 1 SYRINGE in 1 POUCH / .3 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)
Approval Date:	Aug 30, 2007	TE:	AB	RLD:	Yes
Regulatory Exclusivity Expiration:	Sep 15, 2024
Regulatory Exclusivity Use:	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)
Approval Date:	Aug 30, 2007	TE:	AB	RLD:	Yes
Regulatory Exclusivity Expiration:	Sep 15, 2024
Regulatory Exclusivity Use:	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;SUBCUTANEOUS			Strength	EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)
Approval Date:	Aug 30, 2007	TE:	AB	RLD:	Yes
Regulatory Exclusivity Expiration:	Sep 15, 2024
Regulatory Exclusivity Use:	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

Expired US Patents for NDA 022074

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007	⤷ Sign Up	⤷ Sign Up
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007	⤷ Sign Up	⤷ Sign Up
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.